What do systematic reviews say?

Any glucocorticoid vs no glucocorticoids or placebo

It is very uncertain whether glucocorticoids changes miscarriage rate per couple compared with no glucocorticoids or placebo (very low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.09 [0.63, 1.87]
  6 studies · 821 participants
  Very low

Any glucocorticoid vs no glucocorticoids or placebo

It is very uncertain whether glucocorticoids changes incidence of ectopic pregnancies per couple compared with no glucocorticoids or placebo (very low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 2.28 [0.33, 15.62]
  3 studies · 320 participants
  Very low

Any glucocorticoid vs no glucocorticoids or placebo

It is very uncertain whether glucocorticoids changes incidence of OHSS per couple (mild–severe) compared with no glucocorticoids or placebo (very low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.07 [0.6, 1.9]
  3 studies · 370 participants
  Very low

Any glucocorticoid vs no glucocorticoids or placebo

It is very uncertain whether glucocorticoids changes incidence of multiple pregnancies per couple compared with no glucocorticoids or placebo (very low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 0.86 [0.33, 2.2]
  4 studies · 504 participants
  Very low

Any glucocorticoid vs no glucocorticoids or placebo

It is very uncertain whether glucocorticoids changes ongoing pregnancy rate per couple compared with no glucocorticoids or placebo (very low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.19 [0.8, 1.76]
  3 studies · 476 participants
  Very low

Any glucocorticoid vs no glucocorticoids or placebo

Glucocorticoids showed no clear difference in clinical pregnancy rate per couple –pregnancy rate per couple… compared with no glucocorticoids or placebo (low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.17 [0.95, 1.44]
  13 studies · 1967 participants
  Low
• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.2 [0.87, 1.67]
  6 studies · 780 participants
  Very low
• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.15 [0.87, 1.5]
  7 studies · 1187 participants
  Very low

Any glucocorticoid vs no glucocorticoids or placebo

It is very uncertain whether glucocorticoids changes clinical pregnancy rate per couple – subgroup IVF compared with no glucocorticoids or placebo (very low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.44 [1, 2.08]
  5 studies · 724 participants
  Very low

Any glucocorticoid vs no glucocorticoids or placebo

It is very uncertain whether glucocorticoids changes clinical pregnancy rate per couple – subgroup ICSI compared with no glucocorticoids or placebo (very low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.08 [0.81, 1.42]
  6 studies · 992 participants
  Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

The review found no eligible studies for this question.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 38 participants
  Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

It is very uncertain whether interventions (vitamin B1, mefenamic acid, tranexamic acid) changes side effects: gastrointestinal disturbances (diarrhoea, lower… compared with placebo or active comparators (desmopressin, sodium diclofenac,… (very low certainty).

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  OR 4.69 [1.2, 18.44]
  1 study · 38 participants
  Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Low
• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Low
• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 110 participants
  Low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Low
• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 290 participants
  Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

Interventions (vitamin B1, mefenamic acid, tranexamic acid) showed no clear difference in side effects: headache compared with placebo or active comparators (desmopressin, sodium diclofenac,… (low certainty).

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  OR 0.58 [0.18, 1.92]
  1 study · 100 participants
  Low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

Interventions (vitamin B1, mefenamic acid, tranexamic acid) showed no clear difference in side effects: vomiting compared with placebo or active comparators (desmopressin, sodium diclofenac,… (low certainty).

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  OR 0.74 [0.25, 2.18]
  1 study · 100 participants
  Low

Ulipristal acetate (all doses) vs placebo

The review found no eligible studies for this question.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Ulipristal acetate (all doses) vs placebo

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Very low

Naproxen vs placebo

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 33 participants
  Low

Naproxen vs placebo

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 33 participants
  Low